Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Prodia Widyahusada TbkPRWDF 82 3-Year FCF Growth Rate is 8.80% as of Jun. 2026, which is 340% above its 10-year median of 2.00. GuruFocus rates PRWDF with a GF Score™ of 82/100. The stock has 1 warning sign investors should review. Among 151 Medical Diagnostics & Research companies, PT Prodia Widyahusada Tbk ranks worse than 56.95% on this metric.
During the past 12 months, PT Prodia Widyahusada Tbk's average Free Cash Flow per Share Growth Rate was 79.10% per year.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 8.80% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was -7.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of PT Prodia Widyahusada Tbk was 127.30% per year. The lowest was -70.50% per year. And the median was 2.00% per year.
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
PT Prodia Widyahusada Tbk 3-Year FCF Growth Rate Related Terms
PRWDF vs TMO, DHR, IDXX: 3-Year FCF Growth Rate Comparison
For the Diagnostics & Research subindustry, PT Prodia Widyahusada Tbk's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Prodia Widyahusada Tbk 3-Year FCF Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, PT Prodia Widyahusada Tbk's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where PT Prodia Widyahusada Tbk's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
PT Prodia Widyahusada Tbk (PRWDF) has a 3-Year FCF Growth Rate of 8.80% as of Jun. 2026. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for PT Prodia Widyahusada Tbk and its competitors. This is 340% above median its historical median of 2.00. According to the industry distribution chart, PT Prodia Widyahusada Tbk ranks #86 out of 151 companies in the Medical Diagnostics & Research industry, placing it in the top 57%.
Is PT Prodia Widyahusada Tbk's 3-Year FCF Growth Rate too high?
PT Prodia Widyahusada Tbk's current 3-Year FCF Growth Rate of 8.80% is 340% above median its 10-year median of 2.00. The Medical Diagnostics & Research industry median 3-Year FCF Growth Rate is 16.50. PT Prodia Widyahusada Tbk's value of 8.80% is 46.7% below this industry median. Based on the distribution chart, PT Prodia Widyahusada Tbk ranks #86 out of 151 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, PT Prodia Widyahusada Tbk has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does PT Prodia Widyahusada Tbk's 3-Year FCF Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, PT Prodia Widyahusada Tbk ranks #86 out of 151 companies for 3-Year FCF Growth Rate. This places PT Prodia Widyahusada Tbk in the lower half of its industry. The industry median 3-Year FCF Growth Rate is 16.50. PT Prodia Widyahusada Tbk's value of 8.80% is 46.7% below this benchmark. While the company's 10-year median is 2.00 vs. the industry median of 16.50, PT Prodia Widyahusada Tbk has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year FCF Growth Rate among Medical Diagnostics & Research companies is 16.50, based on 151 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Prodia Widyahusada Tbk's current 3-Year FCF Growth Rate of 8.80% is 46.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for PT Prodia Widyahusada Tbk and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year FCF Growth Rate is 16.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Prodia Widyahusada Tbk's current 3-Year FCF Growth Rate is 8.80%, which is 340% above median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Prodia Widyahusada Tbk stock overvalued right now?
PT Prodia Widyahusada Tbk (PRWDF) has a current 3-Year FCF Growth Rate of 8.80%. The current 3-Year FCF Growth Rate is 8.80%, which is 340% above median its 10-year median of 2.00 and 46.7% below the Medical Diagnostics & Research industry median of 16.50. PT Prodia Widyahusada Tbk's overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For PT Prodia Widyahusada Tbk (PRWDF), the current 3-Year FCF Growth Rate is 8.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PT Prodia Widyahusada Tbk provides health care testing services. The company provides analytic and diagnostic services for the medical professionals. It is engaged in health laboratories by conducting business activities such as setting up clinics, health laboratories, management of hospitals, and health checkup services. Its operating segments are Central: Jakarta; Sumatera: Sumatera, Kepulauan Riau; Greater Jakarta: Jakarta, Bogor, Depok, Tangerang, Bekasi, Lampung, Pangkal Pinang; West Java; Central Java; East Java, Bali, Nusa Tenggara; Kalimantan Sulampua: Kalimantan, Sulawesi, Ambon, Papua.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRWDF has been successfully added to your 
